Gain Therapeutics, Inc. Stock Price, News & Analysis

Gain Therapeutics (GANX) announced positive topline data from a study on its compounds GT-02287 and GT-02329 for treating Gaucher and GBA1 Parkinson's Disease. The study showed increased GCase protein levels and activity, along with a decrease in toxic α-synuclein levels. Conducted in collaboration with the University of Maryland School of Medicine, findings will be presented in a webinar organized by the Michael J. Fox Foundation. The company plans to initiate IND-enabling studies for these treatments in Q4 2021.

Gain Therapeutics (Nasdaq: GANX), a biotechnology company specializing in neurodegenerative and lysosomal storage disorders, announced that CEO Eric Richman will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. An on-demand presentation will be available starting September 13, 7:00 am ET for 90 days. Richman and CFO Salvatore Calabrese are available for virtual 1x1 meetings during the conference. Gain is focused on innovative drug discovery and is supported by organizations like The Michael J. Fox Foundation.

Gain Therapeutics, Inc. (GANX) reported a cash position of $43.16 million as of June 30, 2021, significantly up from $7.49 million at the end of 2020. The company continues to advance its developmental programs while expanding its intellectual property portfolio, including two new patents targeting misfolded proteins linked to neurodegenerative diseases. Revenues for Q2 2021 reached $89,000, up from $7,000 in Q2 2020, primarily due to collaboration with Zentalis Pharmaceuticals. However, net losses increased to $3.56 million compared to $543,000 a year earlier.

Gain Therapeutics (Nasdaq: GANX) announced that CEO Eric Richman will present a corporate overview at the BTIG Virtual Biotechnology Conference on August 9-10, 2021. His presentation is scheduled for 11:30 to 11:55 a.m. ET on August 9. Gain Therapeutics specializes in drug discovery targeting protein misfolding associated with neurodegenerative diseases and lysosomal storage disorders. The event expects participation from over 120 management teams and offers thematic panels and one-on-one meetings.

Gain Therapeutics (Nasdaq: GANX) announced the issuance of two PCT patents on June 10, 2021, targeting compounds for misfolded enzymes associated with neurodegenerative and lysosomal storage diseases. The patents include PCT/IB2020/061158, which addresses diseases like Gaucher Disease and Parkinson’s Disease, and PCT/IB2020/061156, focused on conditions linked to GALC alterations. CEO Eric Richman emphasized this as a significant milestone for developing new therapies for these challenging diseases, reinforcing the company's intellectual property and commitment to innovation.

Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology firm, will present a corporate overview at the Jefferies Virtual Healthcare Conference from June 1 to June 4, 2021. CEO Eric Richman is set to speak on June 1 at 3:00 PM ET. The session will be accessible via webcast and will be available for replay on the company's website for 30 days post-conference. This annual conference gathers over 400 healthcare companies and 3,000 investors to discuss investment opportunities and trends in healthcare.

Gain Therapeutics, Inc. (Nasdaq: GANX) announced that CEO Eric Richman will present a corporate overview at the 2021 RBC Capital Markets Global Healthcare Virtual Conference on May 19 at 9:10 a.m. ET and at the Oppenheimer Rare & Orphan Disease Summit on May 21 at 8:15 a.m. ET. Both presentations will highlight Gain's innovative drug discovery approach using its SEE-Tx™ platform to target allosteric binding sites, addressing challenging disorders linked to protein misfolding. Webcast links for the events are available on the company’s website.

Gain Therapeutics, Inc. (Nasdaq: GANX) has successfully completed its IPO, raising approximately $46 million in gross proceeds. The company has appointed four independent board members to enhance leadership and signed a collaboration agreement with Zentalis Pharmaceuticals to develop cancer treatments. Positive pre-clinical data was presented at the WorldSymposium™. For Q1 2021, the company reported net loss of $2.45 million with cash reserves of $46.59 million.

Gain Therapeutics, Inc. (NASDAQ: GANX) announced promising pre-clinical data from its GBA1 Parkinson's disease program at the IAPRD World Congress. The data highlights the potential of their Structurally Targeted Allosteric Regulators (STARs), which stabilize and restore activity of mutated GCase, leading to decreased levels of phosphorylated and aggregated α-synuclein. Key candidates GT-02287 and GT-02329 were effective in reversing neurodegeneration in animal models, suggesting a new therapeutic avenue for GBA1-related Parkinson's disease. The research was recognized as one of the top 10 abstracts presented at the conference.